Could serum intestinal fatty acid-binding protein and citrulline levels be predictive markers of mortality in critically ill COVID-19 patients?

Sevda Onuk; Nurhayat Tugra Ozer; Serap Sahin Ergul; Esma Eryilmaz Eren; Cigdem Karakukcu; Hilal Sipahioglu; Aynur Karayol Akin; Kursat Gundogan

doi:10.3855/jidc.20862

Could serum intestinal fatty acid-binding protein and citrulline levels be predictive markers of mortality in critically ill COVID-19 patients?

Authors

Sevda Onuk Department of Intensive Care Unit, Kayseri City Training and Research Hospital, Kayseri, Turkey
Nurhayat Tugra Ozer Department of Clinical Nutrition, Health Science Institute, Erciyes University, Kayseri, Turkey
Serap Sahin Ergul Department of Clinical Nutrition, Health Science Institute, Erciyes University, Kayseri, Turkey
Esma Eryilmaz Eren Department of Infectious Disease, Kayseri City Training and Research Hospital, Kayseri, Turkey https://orcid.org/0000-0002-2712-9694
Cigdem Karakukcu Department of Clinical Biochemistry, Erciyes University, Kayseri, Turkey
Hilal Sipahioglu Department of Intensive Care Unit, Kayseri City Training and Research Hospital, Kayseri, Turkey
Aynur Karayol Akin Department of Anesthesiology and Reanimation Intensive Care, School of Medicine, Erciyes University, Kayseri, Turkey
Kursat Gundogan Department of Clinical Nutrition, Health Science Institute, Erciyes University, Kayseri, Turkey

DOI:

https://doi.org/10.3855/jidc.20862

Keywords:

Citrulline, COVID-19, intensive care unit, intestinal (dys)function, intestinal fatty acid binding protein

Abstract

Introduction: The global Coronavirus Disease 2019 (COVID-19) pandemic has been demonstrated to cause severe acute respiratory syndrome and is frequently associated with gastrointestinal (GI) manifestations. Intestinal fatty acid binding protein (IFABP) and citrulline have been identified as potential biomarkers of intestinal (dys)function. The present study was undertaken to ascertain the relationship between serum IFABP and citrulline concentrations and mortality in patients with COVID-19.

Methodology: This observational study was conducted in the medical intensive care unit (ICU) and included adult patients diagnosed with PCR-confirmed cases of severe acute respiratory syndrome (SARS-CoV-2). Serum citrulline and IFABp concentrations were quantitatively analyzed using an enzyme-linked immunosorbent assay (ELISA) within the initial 24 hours following ICU admission.

Results: A total of 85 critically ill patients (mean age: 70.0  12.4 years) were recruited for this study. The mean Acute Physiology and Chronic Health Evaluation (APACHE II) score was 20.0  7.1. In comparison with survivors (n = 48 patients), non-survivors (n = 37 patients) exhibited significantly elevated serum IFABp concentrations (median (interquartile range, IQR): 13.27 [6.41-17.87] vs. 7.23 [3.26-12.25] ng/mL, p = 0.007) and diminished citrulline levels (median (IQR): 7.61 [4.37-8.52] vs. [4.67 (3.34-8.90] nmol/L, p = 0.043). Receiver operating characteristic (ROC) analysis revealed that the cut off value of serum IFABp and citrulline concentrations to predict ICU mortality was 8.15 ng/mL (AUC: 0.722, 95% Cl: 0.611-0.833, p = 0.001) and 5.99 nmol/L (AUC: 0.671, 95% Cl: 0.551-0.791, p = 0.009), respectively.

Conclusions: The findings of this study indicate that serum IFABP and citrulline concentrations possess the potential to function as biomarkers for predicting mortality in critically ill patients with confirmed cases of SARS-CoV-2.

Downloads

Published

2025-07-28

How to Cite

Onuk S, Ozer NT, Sahin Ergul S, Eryilmaz Eren E, Karakukcu C, Sipahioglu H, Karayol Akin A, Gundogan K (2025) Could serum intestinal fatty acid-binding protein and citrulline levels be predictive markers of mortality in critically ill COVID-19 patients?. J Infect Dev Ctries 19:1024–1029. doi: 10.3855/jidc.20862

Download Citation

Endnote/Zotero/Mendeley (RIS)

Issue

Vol. 19 No. 07: July 2025

Section

Coronavirus Pandemic

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).